Nexus Pharms Company Profile

What is the competitive landscape for NEXUS PHARMS, and what generic alternatives to NEXUS PHARMS drugs are available?

NEXUS PHARMS has fourteen approved drugs.

There are two US patents protecting NEXUS PHARMS drugs.

There are seven patent family members on NEXUS PHARMS drugs in seven countries and seventy-one supplementary protection certificates in eight countries.

Summary for Nexus Pharms

International Patents:	7
US Patents:	2
Tradenames:	16
Ingredients:	14
NDAs:	14

Drugs and US Patents for Nexus Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nexus Pharms	LEVETIRACETAM IN SODIUM CHLORIDE	levetiracetam	INJECTABLE;INTRAVENOUS	213532-002	Jul 6, 2020	AP	RX	No	No
Nexus Pharms	DICYCLOMINE HYDROCHLORIDE	dicyclomine hydrochloride	INJECTABLE;INJECTION	206468-001	Feb 1, 2019	AP	RX	No	No
Nexus Pharms	EMERPHED	ephedrine sulfate	SOLUTION;INTRAVENOUS	213407-001	Apr 17, 2020		RX	Yes	Yes	11,090,278
Nexus Pharms	TESTOSTERONE ENANTHATE	testosterone enanthate	INJECTABLE;INJECTION	040575-001	Jun 14, 2006	AO	RX	No	No
Nexus Pharms	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	213552-001	Oct 27, 2020	AP	RX	No	No
Nexus Pharms	EMERPHED	ephedrine sulfate	SOLUTION;INTRAVENOUS	213407-001	Apr 17, 2020		RX	Yes	Yes	11,241,400

International Patents for Nexus Pharms Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	3968975
Israel	288044
Australia	2020276619
South Korea	20220009985
China	113825500
World Intellectual Property Organization (WIPO)	2020232424

Supplementary Protection Certificates for Nexus Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0480717	98C0022	France		PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
1441735	SPC/GB08/020	United Kingdom		PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
0480717	SPC/GB98/025	United Kingdom		PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
0145340	99C0005	Belgium		PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
2203431	15C0013	France		PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
2932970	SPC/GB18/041	United Kingdom		PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Nexus Pharms